No Data
Qianyuan Pharmaceutical: Report for the first quarter of 2025
Qianyuan Pharmaceutical: 2024 Annual Report
Qianyuan Pharmaceutical: 2024 Annual Report Summary
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Shanxi C&Y Pharmaceutical Group (300254.SZ): Jiayi Pharmaceutical has been re-certified as a high-tech enterprise.
On February 10, Ge Long Hui reported that Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its holding subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. (referred to as "Jiayi Pharmaceutical") learned from the announcement released by the Office of the Leading Group for the Management of National High-tech Enterprise Recognition that Jiayi Pharmaceutical has passed the re-recognition as a high-tech enterprise, with certificate number: GR202432014625, issue date December 16, 2024, and valid for three years.
ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
